Uniting Large Pharma, Innovative Biotech & Leading Academics to Unleash the Full Potential of RAS-Targeting Drugs for Precision Oncology
Returning for its 7th year, the RAS-Targeted Drug Development Summit remains the only industry-focused meeting dedicated to targeting all RAS mutations in the fight against a wide array of cancers.
The 2025 summit is showcasing forward thinking RAS leaders with brand new innovations, from degraders, cell therapies, vaccines, small molecule inhibitors and more, to target G12C, G12D, Q61, NRAS – mutations and beyond.
With Revolution Medicines dosing their first subject in phase III NSCLC trial, we are now more than ever witnessing this industry make great strides. However, treating RAS mutant cancers remains no easy feat, as knowledge gaps persist in improving the durability of response, tackling emerging resistance mechanisms and informing combination strategies to improve the standard-of care for patients in need.
Join Pfizer, Amgen, PAQ Therapeutics, Aethon Therapeutics, and many others at the 7th RAS-Targeted Drug Development Summit to gain a wealth of actionable insights across the end-to-end drug development pipeline for RAS-targeting drugs.
This summit is one of the few and best forums focusing on RAS-targeting drugs for industry leaders and researchers. It is extremely helpful as several classes of KRAS inhibitors and degraders are in clinical development.
Huaixiang Hao,Vice President, Head, Research, PAQ TherapeuticsÂ
This is an excellent meeting to present strategies and new preclinical and clinical data targeting RAS pathway-driven cancers, and to interact with colleagues from both academia and industry. Several of our ongoing collaborations can be traced back to these Hanson Wade conferences.
Jonathan Pachter, Chief Scientific Officer, Verastem Oncology
A wonderful opportunity to participate in a comprehensive RAS focused conference with diverse coverage of multiple approaches (SMIs & biologics) that target RAS with the end game to expeditiously deliver novel therapies to patients.
Michael Niedbala, Executive Director, Early Oncology Projects, AstraZenecaFirstÂ
Explore the Full Event Guide
- The Only Industry Dedicated RAS Forum
- 40+ World Class Speakers
- 3 Exclusive Days of Data Driven Content
- 2 Deep Dive Workshop Sessions
- 1 Combination Strategies Focus Day
Attending Companies Include
Explore Related Events
Explore the Agenda
Hear the latest industry breakthroughs, cutting edge strategies as well as overcome RAS drug bottlenecks during our packed agenda consisting of deep dive workshops, interactive roundtables and data-driven case studies.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of RAS biopharma deals.
Join RAS Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.